Sean McAuliffe
Chief Business Officer
Sean McAuliffe has served as Chief Business Officer at Taysha Gene Therapies since 2023.
Sean is a seasoned business and commercial leader with over 25 years of experience and a proven record of driving product launches, strategic alliances, commercial growth and marketing across the biopharmaceutical industry. Before joining Taysha, Sean served as Vice President of U.S. Marketing at AveXis, where he developed and implemented the company’s commercial strategies, including the go-to-market plan for Zolgensma for the treatment of spinal muscular atrophy, the first U.S. FDA approved one-time gene therapy to treat a monogenic CNS disorder, which has reached blockbuster status. Before AveXis, Sean served as Vice President of Commercial at a private equity backed start-up where he led business development, sales and distribution for an acquired asset. Sean has also held roles of increasing responsibility in sales and marketing at Takeda, Merck, Baxter Healthcare, Baxalta, and SagePath Medical, contributing to the approval and commercialization of multiple drugs and biological products.
Sean earned a B.A. in communications from the University of Minnesota-Duluth.
